Does body mass index matter in predicting renal mass sizes? Comparison of imaging modalities.

Authors

null

Young Son

Jefferson New Jersey, Philadelphia, PA

Young Son , Benjamin Fink , Brian Thomas , Dayna DeVincentz , Raeann Dalton , Thomas Mueller , Gordon Andrew Brown

Organizations

Jefferson New Jersey, Philadelphia, PA, Rowan University, Stratford, NJ, Rowan University, Glassboro, NJ, Jefferson New Jersey, Stratford, NJ, Delaware Valley Urol, Sewell, NJ

Research Funding

No funding received
None.

Background: Renal cell carcinoma is most commonly diagnosed as an incidental mass detected on cross sectional imaging. When a renal mass is thought to be cancerous, size on imaging is important for clinical decision-making, as there is a known positive correlation with increasing size prognostic outcomes. Image quality may be adversely impacted by a variety of factors, and we sought to assess the impact of body mass index (BMI) on the ability to obtain accurate renal mass sizes across multiple imaging modalities. Methods: A retrospective multi-institutional chart review was performed for adult patients undergoing partial or radical nephrectomy between January 2018 and December 2021 from three different hospitals and six operating surgeons. BMI groups were assigned by BMI 1: <18.5, BMI 2: 18.5-24.9, BMI 3: 25-29.9, BMI 4: 30-34.9, and BMI 5: >35. Differences between greatest dimensions were compared between pathological measurement and each imaging modality: computerized tomography (CT) with and without contrast, ultrasound (US), and magnetic resonance imaging (MRI). Paired t test was used to analyze the total cohort mean difference testing for a difference between modalities and pathology report. T-tests and Wilcoxon signed-rank tests were used to compare the different BMI groups. Results: A total of 234 patients met inclusion criteria and were identified by age, gender, procedure, and renal mass location. There was a statistically significant difference between the greatest dimension as measured on CT with contrast and MRI compared to pathological measurement in the total cohort. Sub analysis of BMI groups showed the differences in size in BMI group 4 (mean (SD)) (0.46 cm (0.52)) and BMI group 5 (0.4 cm (0.51)) were found to have a significant difference in size estimates compared to BMI 3 for CT with contrast (Table). There was no difference for size estimates by BMI group for any other imaging modality. Conclusions: While CT with contrast and MRI are important modalities for their tissue enhancement abilities, they may not be the strongest choice for strict renal mass size estimation. Specifically, CT with contrast becomes less accurate at estimating mass size for patients with BMI >30.

Differences in pathological and radiological measurements of renal masses and comparison between BMI.

Mean Differences in cm (SD)CT w/ Contrast
(n=80)
CT w/o Contrast
(n=41)
MRI w/ Contrast
(n=115)
Ultrasound
(n=49)
Total Cohort 0.21 (0.72)-0.11 (0.85)0.14 (0.76)-0.04 (1.45)
BMI 2-0.03 (0.49)0.4 (0.57)0.18 (0.58)0.22 (0.7)
BMI 3 -0.03 (0.93)-0.32 (0.74)0.08 (1.0)0.2 (1.2)
BMI 4 0.46 (0.52)0.48 (1.01)0.2 (0.59)-0.05 (1.1)
BMI 5 0.4 (0.51)-0.38 (0.76)0.16 (0.61)-0.8 (2.4)
p-values
Total Cohort Mean Difference 0.010.400.040.54
BMI 3 vs. BMI 2 0.990.150.610.95
BMI 3 vs. BMI 40.020.050.520.57
BMI 3 vs. BMI 5 0.040.860.700.27

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2023 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral and Testicular Cancers

Track

Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer

Sub Track

Diagnostics and Imaging

Citation

J Clin Oncol 41, 2023 (suppl 6; abstr 619)

DOI

10.1200/JCO.2023.41.6_suppl.619

Abstract #

619

Poster Bd #

E9

Abstract Disclosures

Similar Abstracts

Abstract

2022 ASCO Genitourinary Cancers Symposium

CT abdomen only for active surveillance in patients with stage I germ cell tumor (GCT): A multi-institutional study.

First Author: Hamed Ahmadi

Abstract

2023 ASCO Annual Meeting

Using deep learning to recognize local advanced rectal cancer in CT images.

First Author: ChunYu Lin

Abstract

2021 ASCO Annual Meeting

Comparative study on iron content detection by energy spectral CT and MRI in MDS patients.

First Author: Yao Zhang